NO172237C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater

Info

Publication number: NO172237C
Authority: NO; Norway
Prior art keywords: alkyl; tetrahydrone; agency; derivatives; preparation
Prior art date: 1986-11-14

Application number

NO874757A

Other languages

English (en)

Norwegian (no)

Other versions

NO874757D0 (no

NO172237B (no

NO874757L (no

Inventor

Quirico Branca

Roland Jaunin

Hans Peter Maerki

Fraenzi Marti

Henri Ramuz

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-14

Filing date

1987-11-13

Publication date

1993-06-23

1987-11-13 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1987-11-13 Publication of NO874757D0 publication Critical patent/NO874757D0/no

1988-05-16 Publication of NO874757L publication Critical patent/NO874757L/no

1993-03-15 Publication of NO172237B publication Critical patent/NO172237B/no

1993-06-23 Publication of NO172237C publication Critical patent/NO172237C/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Organic Insulating Materials (AREA)
Luminescent Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Hydrogenated Pyridines (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

NO874757A 1986-11-14 1987-11-13 Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater NO172237C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH456586		1986-11-14

Publications (4)

Publication Number	Publication Date
NO874757D0 NO874757D0 (no)	1987-11-13
NO874757L NO874757L (no)	1988-05-16
NO172237B NO172237B (no)	1993-03-15
NO172237C true NO172237C (no)	1993-06-23

Family

ID=4278454

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO874757A NO172237C (no)	1986-11-14	1987-11-13	Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater
NO1998001C NO1998001I1 (no)	1986-11-14	1998-01-09	Mibefradil

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO1998001C NO1998001I1 (no)	1986-11-14	1998-01-09	Mibefradil

Country Status (31)

Country	Link
US (1)	US4808605A (fr)
EP (1)	EP0268148B1 (fr)
JP (1)	JP2504490B2 (fr)
KR (1)	KR960004863B1 (fr)
CN (1)	CN1028991C (fr)
AT (1)	ATE70267T1 (fr)
AU (1)	AU600769B2 (fr)
BG (1)	BG60937B2 (fr)
CA (1)	CA1319144C (fr)
CS (2)	CS264350B2 (fr)
DE (2)	DE19775076I2 (fr)
DK (1)	DK171349B1 (fr)
DZ (1)	DZ1142A1 (fr)
ES (1)	ES2040234T3 (fr)
FI (1)	FI94414C (fr)
GR (1)	GR3004029T3 (fr)
HK (1)	HK110494A (fr)
HU (1)	HU215915B (fr)
IE (1)	IE60695B1 (fr)
IL (1)	IL84407A (fr)
LV (1)	LV5745B4 (fr)
MC (1)	MC1883A1 (fr)
MX (1)	MX173614B (fr)
NL (1)	NL970019I2 (fr)
NO (2)	NO172237C (fr)
NZ (1)	NZ222474A (fr)
PH (1)	PH23919A (fr)
PT (1)	PT86130B (fr)
SG (1)	SG114194G (fr)
ZA (1)	ZA878362B (fr)
ZW (1)	ZW20087A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2003283A1 (fr) *	1988-12-05	1990-06-05	C. Anne Higley	Imidazoles pour le traitement de l'atherosclerose
CA2011461A1 (fr) *	1989-03-20	1990-09-20	Urs Hengartner	Derives de tetrahydronaphthalene
NL9001522A (nl) *	1990-07-04	1992-02-03	Schreiner Luchtvaart	Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen.
TW216770B (fr) *	1991-07-23	1993-12-01	Hoffmann La Roche
US5674863A (en) *	1991-10-18	1997-10-07	Genentech, Inc.	Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) *	1991-10-18	1993-10-05	Genentech, Inc.	Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
EP0793653A1 (fr) *	1994-11-23	1997-09-10	Neurogen Corporation	Certains derives 4-aminomethyl 2-substitues de l'imidazole et derives 2-aminomethyl 4-substitues de l'imidazole, nouvelles categories de ligands specifiques du sous-type du recepteur de la dopamine
ATE215108T1 (de)	1995-06-23	2002-04-15	Univ Delft Tech	Verfahren zur herstellung eines schäumbaren filmes
TR199700018A2 (tr)	1996-01-31	1997-08-21	Hoffmann La Roche	Alfa,beta-doymamis organik karboksilik asitlerin imaline yönelik proses.
US5808088A (en) *	1997-04-30	1998-09-15	Roche Colorado Corporation	Preparation of mibefradil via an acetamide anion
US5811557A (en) *	1997-04-30	1998-09-22	Roche Colorado Corporation	Preparation of mibefradil via an acetonitrile anion
US5811556A (en) *	1997-04-30	1998-09-22	Roche Colorado Corporation	Preparation of mibefradil via a naphthalenylacetic acid
US6897305B2 (en) *	1998-06-08	2005-05-24	Theravance, Inc.	Calcium channel drugs and uses
US7101909B2 (en) *	1998-10-12	2006-09-05	Theravance, Inc.	Calcium channel drugs and uses
NZ516782A (en) *	1999-07-28	2004-12-24	Ortho Mcneil Pharm Inc	Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
AU2001235363A1 (en) *	2000-02-25	2001-09-03	Novo-Nordisk A/S	Mibefradil analogues and their use
WO2001062741A1 (fr) *	2000-02-25	2001-08-30	South Alabama Medical Science Foundation	Derives de tetrahydronaphtalene et leur utilisation
EP1156120B1 (fr) *	2000-05-08	2006-11-22	Pfizer Products Inc.	Résolution enzymatique des modulateurs sélectives du recepteur d'estrogène
FR2827862A1 (fr) *	2001-07-27	2003-01-31	Lipha	Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique
JP2005508949A (ja) *	2001-10-10	2005-04-07	アリックスセラピューティクス	高血圧および狭心症の治療に有用なカルシウムチャネル遮断剤であるミベフラジルをベースとした化合物
KR20030037081A (ko) *	2001-11-02	2003-05-12	한국과학기술연구원	Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
BR0313593A (pt)	2002-08-19	2005-07-12	Pfizer Prod Inc	Terapia de combinação para doenças hiperproliferativas
US20050037063A1 (en) *	2003-07-21	2005-02-17	Bolton Anthony E.	Combined therapies
CN1856490A (zh) *	2003-07-28	2006-11-01	詹森药业有限公司	苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
KR20070054644A (ko) *	2004-07-26	2007-05-29	액테리온 파마슈티칼 리미티드	미립자 제형으로 흡입된 일로프로스트에 의한 폐고혈압의치료
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
EP2111863B1 (fr)	2005-10-26	2012-03-28	Asahi Kasei Pharma Corporation	Combinaison du fasudil et bosentan pour le traitement de l'hypertension artérielle pulmonaire
EP2351569B1 (fr)	2005-10-26	2012-08-22	Asahi Kasei Pharma Corporation	Fasudil dans des thérapies combinées pour le traitement de l'hypertension artérielle pulmonaire
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
ATE547394T1 (de)	2006-12-01	2012-03-15	Bristol Myers Squibb Co	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
TW200906396A (en) *	2007-02-14	2009-02-16	Janssen Pharmaceutica Nv	LTA4H modulators and uses thereof
WO2008132679A1 (fr) *	2007-04-27	2008-11-06	Actelion Pharmaceuticals Ltd	Composés pontés de cycles à six chaînons
SI2336125T1 (sl) *	2008-04-11	2013-04-30	Janssen Pharmaceutica N.V.	Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze
EP2271628A1 (fr) *	2008-04-25	2011-01-12	Actelion Pharmaceuticals Ltd.	Dérivés de benzimidazole en tant que bloqueurs des canaux calciques
KR20110079736A (ko) *	2008-10-22	2011-07-07	액테리온 파마슈티칼 리미티드	가교된 테트라하이드로나프탈렌 유도체
WO2010046729A2 (fr) *	2008-10-23	2010-04-29	Actelion Pharmaceuticals Ltd	Composés tétrahydronaphthalène
JP6205133B2 (ja)	2009-07-10	2017-09-27	プレジデントアンドフェローズオブハーバードカレッジ	抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
US8575361B2 (en)	2010-03-02	2013-11-05	Concert Pharmaceuticals Inc.	Tetrahydronaphthalene derivatives
EP2542534A1 (fr)	2010-03-02	2013-01-09	Concert Pharmaceuticals Inc.	Dérivés de tétrahydronaphtalène deutérés
WO2012037665A1 (fr)	2010-09-24	2012-03-29	Oral Delivery Technology Ltd.	Oxyde nitrique libérant un ester d'acide aminé pour le traitement de l'hypertension pulmonaire et autres états respiratoires
CA2909442A1 (fr)	2013-04-17	2014-10-23	Pfizer Inc.	Derives de n-piperidin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
CA3002831C (fr)	2015-10-22	2024-04-16	Cavion, Inc.	Procedes pour traiter le syndrome d'angelman et des troubles associes
US11130750B2 (en)	2017-02-15	2021-09-28	Cavion, Inc.	Calcium channel inhibitors
SG11201909960UA (en)	2017-04-26	2019-11-28	Cavion Inc	Methods for improving memory and cognition and for treating memory and cognitive disorders
BR112021006398A2 (pt)	2018-10-03	2021-07-06	Cavion Inc	tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida
HUE069590T2 (hu)	2019-01-18	2025-03-28	Astrazeneca Ab	PCSK9-gátló 6'-[[(1s,3s)-3-[[5-(difluormetoxi)-2-pirimidinil]amino]ciklopentil]amino][1(2h ),3'-bipiridin]-2-on és alkalmazására szolgáló eljárások
CN115850119A (zh) *	2022-11-26	2023-03-28	南昌大学	一种2-氯芳香胺类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3914216A (en) *	1962-12-18	1975-10-21	Boehringer Sohn Ingelheim	1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones
BE793460A (fr) *	1971-12-29	1973-06-28	Boehringer Sohn Ingelheim	Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h
NZ213651A (en) *	1984-10-11	1989-07-27	Hoffmann La Roche	Tetrahydronapthalene derivatives and medicaments

1987
- 1987-10-26 DK DK559987A patent/DK171349B1/da not_active IP Right Cessation
- 1987-10-26 CA CA000550190A patent/CA1319144C/fr not_active Expired - Fee Related
- 1987-11-03 ZW ZW200/87A patent/ZW20087A1/xx unknown
- 1987-11-03 CS CS877874A patent/CS264350B2/cs not_active IP Right Cessation
- 1987-11-04 EP EP87116251A patent/EP0268148B1/fr not_active Expired - Lifetime
- 1987-11-04 AT AT87116251T patent/ATE70267T1/de active
- 1987-11-04 DE DE1997175076 patent/DE19775076I2/de active Active
- 1987-11-04 ES ES198787116251T patent/ES2040234T3/es not_active Expired - Lifetime
- 1987-11-04 DE DE8787116251T patent/DE3775177D1/de not_active Expired - Lifetime
- 1987-11-06 ZA ZA878362A patent/ZA878362B/xx unknown
- 1987-11-06 NZ NZ222474A patent/NZ222474A/xx unknown
- 1987-11-09 IL IL84407A patent/IL84407A/xx unknown
- 1987-11-09 AU AU80909/87A patent/AU600769B2/en not_active Ceased
- 1987-11-10 US US07/119,114 patent/US4808605A/en not_active Expired - Lifetime
- 1987-11-10 JP JP62282287A patent/JP2504490B2/ja not_active Expired - Lifetime
- 1987-11-11 HU HU875011A patent/HU215915B/hu not_active IP Right Cessation
- 1987-11-11 DZ DZ870191A patent/DZ1142A1/fr active
- 1987-11-11 PH PH36056A patent/PH23919A/en unknown
- 1987-11-12 MX MX009271A patent/MX173614B/es unknown
- 1987-11-12 MC MC871928A patent/MC1883A1/fr unknown
- 1987-11-13 KR KR87012777A patent/KR960004863B1/ko not_active Expired - Fee Related
- 1987-11-13 FI FI875024A patent/FI94414C/fi not_active IP Right Cessation
- 1987-11-13 IE IE307087A patent/IE60695B1/en not_active IP Right Cessation
- 1987-11-13 NO NO874757A patent/NO172237C/no not_active IP Right Cessation
- 1987-11-13 CN CN87107875A patent/CN1028991C/zh not_active Expired - Fee Related
- 1987-11-13 PT PT86130A patent/PT86130B/pt not_active IP Right Cessation
1991
- 1991-12-20 CS CS913948A patent/CS394891A3/cs unknown
1992
- 1992-03-11 GR GR920400420T patent/GR3004029T3/el unknown
1994
- 1994-02-14 BG BG098469A patent/BG60937B2/bg unknown
- 1994-08-13 SG SG114194A patent/SG114194G/en unknown
- 1994-10-12 HK HK110494A patent/HK110494A/xx not_active IP Right Cessation
1996
- 1996-05-24 LV LV960155A patent/LV5745B4/xx unknown
1997
- 1997-05-27 NL NL970019C patent/NL970019I2/nl unknown
1998
- 1998-01-09 NO NO1998001C patent/NO1998001I1/no unknown

Also Published As

Publication number	Publication date
BG60937B2 (bg)	1996-06-28
PH23919A (en)	1990-01-23
HK110494A (en)	1994-10-21
NO1998001I1 (no)	1998-01-09
DK171349B1 (da)	1996-09-16
HUT60251A (en)	1992-08-28
AU600769B2 (en)	1990-08-23
JP2504490B2 (ja)	1996-06-05
MX173614B (es)	1994-03-18
LV5745B4 (lv)	1996-12-20
LV5745A4 (lv)	1996-10-20
MC1883A1 (fr)	1989-01-24
DE3775177D1 (de)	1992-01-23
DE19775076I2 (de)	2001-08-09
NZ222474A (en)	1990-02-26
NL970019I2 (nl)	1997-11-03
EP0268148A1 (fr)	1988-05-25
KR880006163A (ko)	1988-07-21
SG114194G (en)	1994-11-25
ATE70267T1 (de)	1991-12-15
FI94414B (fi)	1995-05-31
AU8090987A (en)	1988-05-19
IL84407A (en)	1991-09-16
IE60695B1 (en)	1994-08-10
CS787487A2 (en)	1988-11-15
CN1028991C (zh)	1995-06-21
EP0268148B1 (fr)	1991-12-11
FI94414C (fi)	1995-09-11
KR960004863B1 (en)	1996-04-16
NL970019I1 (nl)	1997-08-01
HU215915B (hu)	1999-03-29
CN87107875A (zh)	1988-05-25
ES2040234T3 (es)	1993-10-16
PT86130A (en)	1987-12-01
CS394891A3 (en)	1992-06-17
NO874757D0 (no)	1987-11-13
DZ1142A1 (fr)	2004-09-13
FI875024A7 (fi)	1988-05-15
GR3004029T3 (fr)	1993-03-31
ZW20087A1 (en)	1988-07-20
IL84407A0 (en)	1988-04-29
NO172237B (no)	1993-03-15
CS264350B2 (en)	1989-07-12
FI875024A0 (fi)	1987-11-13
JPS63139171A (ja)	1988-06-10
DK559987A (da)	1988-05-15
DK559987D0 (da)	1987-10-26
US4808605A (en)	1989-02-28
NO874757L (no)	1988-05-16
IE873070L (en)	1988-05-14
PT86130B (pt)	1990-11-20
MX9271A (es)	1993-09-01
ZA878362B (en)	1988-05-16
CA1319144C (fr)	1993-06-15

Publication	Publication Date	Title
NO172237C (no)	1993-06-23	Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater
NO176356C (no)	1995-03-22	Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser
NO168300C (no)	1992-02-05	Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive imidazoliumsalter
NO941977L (no)	1994-07-29	Indolderivater, fremgangsmåte for fremstilling av disse, og medisinsk anvendelse derav
NO161971C (no)	1989-10-18	Analogifremgangsmaate ved fremstilling av tetrahydronaftalinderivater.
NO881835L (no)	1988-10-31	Fremgangsmaate for fremstilling av terapeutisk aktive bicykliske forbindelser.
NO168037C (no)	1992-01-08	Analogifremgangsmaate ved fremstilling av terapeutisk aktive purin-derivater.
IE44154L (en)	1977-01-14	1,3,8-triazaspiro(4,5) decan-4-one derivatives
NO171639C (no)	1993-04-14	Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolpyrazolderivater
AU6360186A (en)	1987-04-16	New 2-(2-thienyl)-imidazo(4,5-c)pyridine derivatives and salts thereof, processes for their preparation and pharmaceutical products containing these
NO177786B (no)	1995-08-14	Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrido-[2,3-bÅ-benzazepin- (og -tiazepin)-5(6H)-on-derivater
JPS57131788A (en)	1982-08-14	1,7-naphthyridine derivative

Legal Events

Date	Code	Title	Description
2003-06-30	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN MAY 2003